| Literature DB >> 26421281 |
Xiao-Yang Liu1, Liang Wang2, Bin Yu2, Qian-Yu Zhuang2, Yi-Peng Wang2.
Abstract
PURPOSE: Adolescent idiopathic scoliosis (AIS), the most common pediatric spinal deformity, is considered a complex genetic disease. Causing genes and pathogenesis of AIS are still unclear. This study was designed to identify differentially expressed long noncoding RNAs (lncRNAs) involving the pathogenesis of AIS.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26421281 PMCID: PMC4569756 DOI: 10.1155/2015/276049
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Detailed information of the four pairs of participants.
| Number | Group | Sex | Height | Age (years) | Illness history (years) | Menarche | Classification | Cobb angle (°) | Risser sign |
|---|---|---|---|---|---|---|---|---|---|
| A1 | AIS | F | 155 | 13.7 | 1 | N | PUMCIIc2 | 50 | 0 |
| A2 | AIS | F | 167 | 15.9 | 2 | Y | PUMCIIc2 | 40 | 4 |
| A3 | AIS | F | 158 | 15.0 | 1 | Y | PUMCIb | 44 | 5 |
| A4 | AIS | F | 159 | 14.2 | 3 | Y | PUMCIIc1 | 44 | 3 |
| N1 | NC | F | 163 | 17.9 | 0 | Y | — | 0 | 5 |
| N2 | NC | F | 163 | 13.2 | 0 | Y | — | 0 | 3 |
| N3 | NC | F | 158 | 12.3 | 0 | N | — | 0 | 0 |
| N4 | NC | F | 170 | 15.5 | 0 | Y | — | 0 | 4 |
Primers used for qPCR.
| lncRNAs | Sense primer (5′-3′) | Antisense primer (5′-3′) | Product (bp) |
|---|---|---|---|
| ENST00000602322.1 | accttcccacctaccagtct | ctggggaaaccaccatagctt | 150 |
| ENST00000440778.1 | acttggttgcttttccccaca | gctttgggcttggaaagatgg | 107 |
| ENST00000414894.1 | agccgccctattcagttcac | tccaagttccgagttgtggg | 148 |
| TCONS_00028768 | gcaaacctggaaatctcggc | ggccgcagacatcatcttct | 142 |
| GAPDH | ctataaattgagcccgcagcc | gcgcccaatacgaccaaatc | 154 |
Figure 1Heat maps of expression ratios (log2 scale) of lncRNAs (a) and mRNAs (b) between AIS patients and normal control. “Red” denotes high relative expression and “blue” denotes low relative expression.
Genes biological processes.
| Biological processes | Gene symbol | Gene name | Entrez gene ID | Fold changes |
|---|---|---|---|---|
| Nervous system development | LTA | “Phosphoinositide-3-kinase, catalytic, delta polypeptide” | 5293 | 2.1513674 |
| TP53 | Tumor protein p53 | 7157 | 2.0308032 | |
| MSH2 | “mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)” | 4436 | 2.0266845 | |
| BCL2 | BCL2-associated athanogene 3 | 9531 | 2.130905 | |
| TP53 | Tumor protein p53 | 7157 | 2.0308032 | |
| NCL | Nuclear RNA export factor 1 | 10482 | 2.00108 | |
| PAFAH1B1 | “Platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 (45 kDa)” | 5048 | 2.1079702 | |
| OLIG1 | Oligodendrocyte transcription factor 1 | 116448 | 2.129439 | |
| PKD1 | Polycystic kidney disease 1 (autosomal dominant) | 2.18849 | ||
| BTG2 | “BTG family, member 2” | 7832 | 2.7636645 | |
|
| ||||
| Skeletal morphogenesis and development | BCL2 | B-Cell CLL/lymphoma 2 | 596 | 2.252202 |
| IL6ST | “Interleukin 6 signal transducer (gp130, oncostatin M receptor)” | 3572 | 2.2222419 | |
| MYC | v-myc myelocytomatosis viral oncogene homolog (avian) | 4609 | 2.768515 | |
| TPP1 | Tripeptidyl peptidase I | 1200 | 2.0187664 | |
| AES | Aminoterminal enhancer of split | 166 | 2.2728803 | |
| ALOX15 | Arachidonate 15-lipoxygenase | 246 | 2.1062436 | |
|
| ||||
| Muscle development and function | BCL2 | B-Cell CLL/lymphoma 2 | 596 | 2.252202 |
| FLI1 | Friend leukemia virus integration 1 | 2313 | 2.2254617 | |
| UTRN | Utrophin | 7402 | 2.1682687 | |
| UTS2 | Urotensin 2 | 10911 | 2.469184 | |
| HIF1A | “Hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)” | 3091 | 2.028285 | |
| TGFBR2 | “Transforming growth factor, beta receptor II (70/80 kDa)” | 7048 | 2.1115046 | |
| TTN | Titin | 7273 | 2.7300012 | |
| LEF1 | Lymphoid enhancer-binding factor 1 | 51176 | 3.1550286 | |
| HIF1A | “Hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)” | 3091 | 2.028285 | |
| FAM65B | “Family with sequence similarity 65, member B” | 9750 | 2.247876 | |
| UTRN | Utrophin | 7402 | 2.1682687 | |
|
| ||||
| Notch signaling pathway | ADAM17 | ADAM metallopeptidase domain 17 | 6868 | 2.0420005 |
| NOTCH2 | Notch 2 | 4853 | 2.1405845 | |
| CTBP1 | C-Terminal binding protein 1 | 1487 | 2.050679 | |
|
| ||||
| MAPK signaling pathway | TAB2 | TGF-beta activated kinase 1/MAP3K7 binding protein 2 | 23118 | 2.1040483 |
| SOS1 | Son of sevenless homolog 1 (Drosophila) | 6654 | 2.0901704 | |
| DUSP16 | Dual specificity phosphatase 16 | 80824 | 2.1876025 | |
| MAP3K1 | Mitogen-activated protein kinase kinase kinase 1 | 4214 | 2.343032 | |
| RPS6KA3 | “Ribosomal protein S6 kinase, 90 kDa, polypeptide 3” | 6197 | 2.0745454 | |
| CD14 | CD14 molecule | 929 | 2.3363564 | |
| DUSP6 | Dual specificity phosphatase 6 | 1848 | 2.2230558 | |
| ARRB1 | “Arrestin, beta 1” | 408 | 2.004528 | |
| TGFBR2 | “Transforming growth factor, beta receptor II (70/80 kDa)” | 7048 | 2.1115046 | |
| AKT3 | “v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)” | 10000 | 2.0013347 | |
| MYC | v-myc myelocytomatosis viral oncogene homolog (avian) | 4609 | 2.768515 | |
| TP53 | Tumor protein p53 | 7157 | 2.0308032 | |
| NFKB1 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | 4790 | 2.0809784 | |
|
| ||||
| Wnt signaling pathway | CAMK2G | Calcium/calmodulin-dependent protein kinase II gamma | 818 | 2.1046312 |
| TCF7 | “Transcription factor 7 (T-cell specific, HMG-box)” | 6932 | 2.6018746 | |
| PPARD | Peroxisome proliferator-activated receptor delta | 5467 | 2.1376982 | |
| TCF3 | “Transcription factor 7 (T-cell specific, HMG-box)” | 6932 | 2.8202255 | |
| CAMK2D | Calcium/calmodulin-dependent protein kinase II delta | 817 | 2.5258021 | |
| PLCB2 | “Phospholipase C, beta 2” | 5330 | 2.2920265 | |
| NFATC1 | “Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1” | 4772 | 2.0340881 | |
| MYC | v-myc myelocytomatosis viral oncogene homolog (avian) | 4609 | 2.768515 | |
| TP53 | Tumor protein p53 | 7157 | 2.0308032 | |
| LEF1 | Lymphoid enhancer-binding factor 1 | 51176 | 3.1550286 | |
| CTBP1 | C-Terminal binding protein 1 | 1487 | 2.050679 | |
| PIAS4 | “Protein inhibitor of activated STAT, 4” | 51588 | 2.0654333 | |
| AES | Aminoterminal enhancer of split | 166 | 2.2728803 | |
| INVS | Inversin | 27130 | 2.2433844 | |
| LRRFIP2 | Leucine rich repeat (in FLII) interacting protein 2 | 9209 | 2.1049194 | |
Gene Ontology and Pathway analysis was performed for differentially expressed mRNAs. mRNAs involving musculoskeletal development are listed in their gene groups with associated Entrez Gene ID and fold changes per gene.
Figure 2CNC network of lncRNA ENST00000602322.1 (labeled as p2444). Circular nodes represent mRNA; triangular nodes represent lncRNA. Detailed information of lncRNAs and mRNAs is listed in supplementary tables.
Correlation between lncRNAs and mRNAs.
| Sourcea | lncRNA | mRNA | Gene symbol | Correlation |
|
|
|---|---|---|---|---|---|---|
| p33784 | uc002ddj.1 | A_21_P0011418 | PKD1 | 0.9967847 | 8.29 | Sense |
| p33788 | uc021tnw.1 | A_24_P282108 | ZZEF1 | 0.9976724 | 3.15 | Sense |
| p26337 | uc021zdc.1 | A_23_P122615 | PNISR | 0.9907335 | 1.98 | Sense |
| p26595 | HIT000067310 | A_23_P391275 | RCAN3 | 0.9967367 | 8.67 | Intergenic |
| p112 | ENST00000577528.1 | A_23_P391275 | RCAN3 | 0.9965706 | 1.01 | Intergenic |
| p2444 | ENST00000602322.1 | A_33_P3210139 | PCF11 | 0.9932224 | 7.74 | Antisense |
| p26595 | HIT000067310 | A_23_P35205 | RCAN3 | 0.9900216 | 2.47 | Sense |
| p29552 | TCONS_00001429 | A_23_P35205 | RCAN3 | 0.9956033 | 2.12 | Antisense |
aProbe name of lncRNA. bsense: the lncRNAs is a coding transcript exon on the same genomic strand; antisense: the lncRNA is transcribed from the antisense strand; intergenic: there are no overlapping or bidirectional coding transcripts nearby the lncRNA within 10 kbp.
Figure 3Comparison between microarray and qPCR results. The columns heights represent the log-transformed median fold changes (AIS/NC) in the AIS patients compared to normal control. The validation results of the four lncRNAs indicate that the microarray results match well the qPCR results.
Expressions of lncRNAs in different clinical features.
| Features | ENST00000602322.1 | ENST00000440778.1 | ENST00000414894.1 | TCONS_00028768 | |
|---|---|---|---|---|---|
| Menarche age (y) | ≤11 | 7.29 ± 0.82 | 4.74 ± 0.88 | 3.04 ± 0.52 | 5.51 ± 1.08 |
| >11 | 7.75 ± 1.20 | 5.09 ± 1.25 | 2.95 ± 0.75 | 5.62 ± 1.44 | |
|
| |||||
| Height (cm) | ≤160 | 7.49 ± 1.03 | 4.40 ± 0.71∗ | 2.98 ± 0.59 | 5.05 ± 0.99∗ |
| >160 | 7.73 ± 1.17 | 5.34 ± 1.45∗ | 2.99 ± 0.78 | 5.95 ± 1.63∗ | |
|
| |||||
| Onset of AIS (y) | ≤12 | 6.73 ± 0.60∗∗ | 4.92 ± 1.09 | 3.09 ± 1.52 | 5.54 ± 1.19 |
| >12 | 7.86 ± 1.29∗∗ | 5.01 ± 1.17 | 2.87 ± 1.17 | 5.63 ± 1.43 | |
|
| |||||
| Numbers of curvesa | 1 | 7.09 ± 0.74∗ | 4.95 ± 1.40 | 2.79 ± 0.66 | 5.81 ± 1.24 |
| 2 | 7.98 ± 1.19∗ | 4.98 ± 0.95 | 3.10 ± 0.66 | 5.46 ± 1.34 | |
|
| |||||
| Cobb angle (°) | ≤40 | 7.60 ± 1.36 | 5.11 ± 1.70 | 2.47 ± 0.63∗ | 5.59 ± 1.60 |
| >40 | 7.58 ± 1.95 | 4.90 ± 0.72 | 3.38 ± 0.65∗ | 5.59 ± 1.15 | |
|
| |||||
| Risser signb | ≤3 | 7.51 ± 1.12 | 4.33 ± 0.81∗ | 2.93 ± 0.60 | 5.37 ± 0.97 |
| >3 | 7.65 ± 1.07 | 5.21 ± 1.25∗ | 3.02 ± 0.72 | 5.76 ± 1.51 | |
Relative lncRNAs levels were normalized to GAPDH (ΔCt = CtlncRNA − CtGAPDH). Results are presented as mean ± standard deviation. ∗ P < 0.05, ∗∗ P < 0.01. aCurves were counted and classified into single, double, and triple curves according to the apex number. bRisser sign refers to the amount of calcification of the human pelvis as a measure of maturity. On a scale of 5, it gives a measurement of ossification progression; the grade of 5 means that skeletal maturity is reached.